Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 7/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401285 | 0.90 | MAP4K4 (0.38) | MAP4K4PIM1KDM4C | |
| SCHEMBL31401315 | 0.89 | HRH3 (0.39) | CHRM4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL31396039 | 0.78 | MAPT (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL31400936 | 0.75 | KCNJ1 (0.39) | — | |
| SCHEMBL31400704 | 0.75 | KCNJ1 (0.39) | — | |
| SCHEMBL31401410 | 0.75 | PDE10A (0.55) | MAP4K4 | |
| SCHEMBL23705697 | 0.69 | DHFR (0.40) | PIM1 | |
| SCHEMBL23706098 | 0.67 | MAP4K4 (0.43) | MAP4K4 | |
| SCHEMBL26970022 | 0.66 | PIM1 (0.37) | PIM1 | |
| SCHEMBL4820774 | 0.66 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |